TY - JOUR
T1 - Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer
AU - Lehtonen, Miikka
AU - Heiskanen, Lauri
AU - Reinikainen, Petri
AU - Kellokumpu-Lehtinen, Pirkko-Liisa
PY - 2020
Y1 - 2020
N2 - Background: In
this retrospective study, we evaluated the biochemical recurrence rate,
metastatic disease progression, and prostate cancer-specific and
overall survival in patients curatively treated with external beam
radiotherapy (EBRT) for early prostate cancer (PC). We also examined the
prognostic effect of comorbidity by Charlson Comorbidity Index (CCI)
and overall performance status by Eastern Clinical Oncology Group (ECOG)
score.Methods: A
total of 665 men treated between 2008 and 2013 were enrolled from
Tampere University Hospital, Finland. Prostate-specific antigen (PSA)
tests and hospital records were used to determine the 5-year survival
for each aforementioned endpoint using a Kaplan-Meyer estimate. To
analyze the impact of the selected prognostic factor, we used a Cox
regression model to calculate the corresponding hazard ratio (HR) and
95% confidence interval (CI).Results: With
a median follow-up-time of 7.12 years, the 5-year overall survival (OS)
after EBRT was 88.9% [86.5 -91.3%], prostate cancer-specific survival
(PCSS) was 97.9% [96.7 -99.1%], metastasis-free survival (MFS) 94.8%
[93.0 -96.6%] and biochemical recurrence-free survival (BRFS) 88.7%
[86.2 -91.2%]. Both CCI (HR = 1.38, [1.25–1.51]) and ECOG score
(HR = 1.63, [1.29–2.05]) declined OS, as well as Gleason score and T
score (P < 0.05). Gleason score and T grade also associated to worse PCSS, MFS and BRFS.Conclusions: CCI
and ECOG score are useful tools in evaluating the overall life
expectancy of the patient after EBRT for PC. T-stage and Gleason score
remain still the major prognostic factors.
AB - Background: In
this retrospective study, we evaluated the biochemical recurrence rate,
metastatic disease progression, and prostate cancer-specific and
overall survival in patients curatively treated with external beam
radiotherapy (EBRT) for early prostate cancer (PC). We also examined the
prognostic effect of comorbidity by Charlson Comorbidity Index (CCI)
and overall performance status by Eastern Clinical Oncology Group (ECOG)
score.Methods: A
total of 665 men treated between 2008 and 2013 were enrolled from
Tampere University Hospital, Finland. Prostate-specific antigen (PSA)
tests and hospital records were used to determine the 5-year survival
for each aforementioned endpoint using a Kaplan-Meyer estimate. To
analyze the impact of the selected prognostic factor, we used a Cox
regression model to calculate the corresponding hazard ratio (HR) and
95% confidence interval (CI).Results: With
a median follow-up-time of 7.12 years, the 5-year overall survival (OS)
after EBRT was 88.9% [86.5 -91.3%], prostate cancer-specific survival
(PCSS) was 97.9% [96.7 -99.1%], metastasis-free survival (MFS) 94.8%
[93.0 -96.6%] and biochemical recurrence-free survival (BRFS) 88.7%
[86.2 -91.2%]. Both CCI (HR = 1.38, [1.25–1.51]) and ECOG score
(HR = 1.63, [1.29–2.05]) declined OS, as well as Gleason score and T
score (P < 0.05). Gleason score and T grade also associated to worse PCSS, MFS and BRFS.Conclusions: CCI
and ECOG score are useful tools in evaluating the overall life
expectancy of the patient after EBRT for PC. T-stage and Gleason score
remain still the major prognostic factors.
U2 - 10.1186/s12885-020-06812-6
DO - 10.1186/s12885-020-06812-6
M3 - Article
SN - 1471-2407
VL - 20
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 324
ER -
